NCT Number: NCT06431945
The project is a national, prospective, multicenter, non-interventional pilot project of screening HCV in PWID in the Czech Republic.
The main goal of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of Hepatitis C and setting up and testing new methods and implementation into the system of social health care.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Brno University Hospital, Brno, Czechia
The project is a national, prospective, multicenter, non-interventional pilot project of screening HCV in PWID in 18 clinical centers in the Czech Republic.
The main goal of the project is the elimination of further transmission of hepatitis C virus and to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of Hepatitis C and setting up and testing new methods and implementation into the system of social health care.
The project will include testing the procedure on a sample of approx. 3,000 PWID which can help to identify weak points in the continuum of care. A methodology for the continuous care of the target group in the early diagnostic and therapeutic stages will be created. Proposal for a system change towards streamlining the screening process.
The project is supported by the European Social Fund (Operational Program Employment plus) and the state budget of the Czech Republic and is registered by the Ministry of Labour and Social Affairs of the Czech Republic under ID: CZ.03.02.02/00/22_005/0000281.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Testing for hepatitis C antibodies determines whether or not you have been exposed to HCV at some point in your life. This testing will be performed in all 3,000 persons who inject drugs enrolled in the project.
RNA is a type of genetic material from HCV that can be detected in the blood. This test will be used as a confirmation of the infection. This testing will be performed in all persons with positive antibody test who will come to clinical center.
Time frame: Until 31. 12. 2025
Time frame: Until 31. 12. 2025
Time frame: Until 31. 12. 2025
Contact information is provided by the study sponsor or research team.
Lucie Mandelova, PhD
CONTACT
Nikola Stourac
CONTACT
Institute of Health Information and Statistics of the Czech Republic
Other Gov
Early Detection of Hepatitis C in Injection Drug Users
Acronym: EDVIP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02996682
Blood-Borne Infections, Communicable Diseases
Shimonoseki, Yamaguchi, Japan
View Trial DetailsNCT06870019
Blood-Borne Infections, Communicable Diseases
Alhambra, California, United States
View Trial DetailsNCT06718530
Blood-Borne Infections, Communicable Diseases
Aviano, Pordenone, Italy
View Trial DetailsNCT07687758
Adenocarcinoma, Blood-Borne Infections
Bangkok, Thailand
View Trial Details